Treating TNBS-induced colitis in rats with probiotics

Area of Science:

• Gastroenterology
• Immunology
• Microbiology

Background:

• Inflammatory bowel disease (IBD), including colitis, presents a significant clinical challenge.
• Trinitrobenzene sulfonic acid (TNBS)-induced colitis in rats serves as a relevant preclinical model for human ulcerative colitis.
• Probiotic compounds are being explored for their therapeutic potential in inflammatory conditions.

Purpose of the Study:

• To evaluate the therapeutic efficacy of Peifeikang, a probiotic compound, in a rat model of colitis.
• To investigate the underlying mechanisms by which Peifeikang exerts its anti-inflammatory effects.

Main Methods:

• Colitis was induced in rats using intrarectal administration of trinitrobenzene sulfonic acid (TNBS).
• Therapeutic effects were assessed by measuring disease activity index, colonic damage, and histopathological scores.
• Inflammatory markers, including myeloperoxidase activity and levels of tumor necrosis factor-alpha (TNF-α) and interleukin-10 (IL-10), were quantified.

Main Results:

• TNBS administration successfully induced colitis, characterized by increased inflammation markers.
• Treatment with Peifeikang, alone or with olsalazine, significantly reduced colitis severity and inflammation.
• Peifeikang treatment modulated cytokine production, decreasing pro-inflammatory TNF-α and increasing anti-inflammatory IL-10.

Conclusions:

• Peifeikang demonstrates significant therapeutic effects in ameliorating TNBS-induced colitis in rats.
• The mechanism involves the modulation of key inflammatory cytokines, TNF-α and IL-10.
• Peifeikang represents a promising probiotic-based therapeutic agent for colitis.